Print

IAVI B002

Trial to Evaluate the Safety and Immunogenicity of an Adjuvanted GSK Investigational HIV Vaccine Administered With Ad35-GRIN Investigational Vaccine

Trial Details:

I Completed
International AIDS Vaccine Initiative (IAVI), GlaxoSmithKline February 28, 2011
Adjuvanted GSK investigational HIV vaccine formulation 1,Adjuvanted GSK investigational HIV vaccine formulation 2,Ad35-GRIN
Adjuvanted GSK investigational HIV vaccine formulation 1 Protein
Adjuvanted GSK investigational HIV vaccine formulation 2 Protein
Ad35-GRIN Viral Vector - Adeno
Kenya, Uganda, Zambia 147
NCT01264445
http://clinicaltrials.gov/ct2/show/NCT01264445?term=hiv+vaccine&lup_s=12%2F11%2F2010&lup_d=30